 Connection
Thomas Flaig to Quinazolines
This is a "connection" page, showing publications Thomas Flaig has written about Quinazolines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.258 |
|
|
|
-
Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep. 2010 Oct; 24(4):1019-28.
Score: 0.077
-
Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. 2010 Sep 07; 103(6):796-801.
Score: 0.077
-
Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37.
Score: 0.069
-
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|